RxDoctor Payments DataLook up a doctor →

Pamela Tuli, MD

Hematology & Oncology · Gulfport, MSNPI 1962684555

Payments from drug & device makers

$40,958in general payments, 2019–2025

Across 1,383 payments — averaging $29.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$9K
  • Eli Lilly$5K
  • Novartis$4K
  • Merck$2K
  • Johnson & Johnson$2K
  • AstraZeneca$1K
  • plus $17K from 54 others

What the payments were for

  • Food & beverage$25,59994%
  • Education$2631%
  • Other$1,2985%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie18$8,660
Eli Lilly3$5,480
Novartis156$3,952
Merck109$1,958
Johnson & Johnson(2 entities)85$1,629
AstraZeneca(2 entities)75$1,381
Genentech USA, Inc.81$1,308
E.r. Squibb & Sons, L.L.C.67$1,223
Incyte Corporation51$1,042
Eisai Inc.48$965
Amgen53$905
Pfizer58$829
Daiichi Sankyo Inc.47$821
Lilly USA, LLC42$782
Gilead(2 entities)27$717
Exelixis Inc.35$695
Sanofi31$623
Bristol Myers Squibb30$566
Takeda Pharmaceuticals U.S.A., Inc.15$373
Bayer22$362
Puma Biotechnology, Inc.22$334
EMD Serono, Inc.14$331
Beigene USA, Inc.14$329
Adaptive Biotechnologies Corporation14$326
Seagen Inc.19$323
Stemline Therapeutics Inc.11$321
Tersera Therapeutics LLC12$306
Pharmacyclics LLC, An Abbvie Company11$273
Rigel Pharmaceuticals, Inc.13$263
Pharmaessentia USA Corporation10$252
GSK13$251
Ipsen Biopharmaceuticals, Inc12$234
Karyopharm Therapeutics Inc.14$221
Astellas Pharma US Inc10$210
Array Biopharma Inc14$202
ADC Therapeutics America, Inc.9$178
Regeneron Healthcare Solutions, Inc.7$142
Sanofi-aventis U.S. LLC3$124
CSL Behring1$122
AVEO Pharmaceuticals, Inc.5$107
Dendreon Pharmaceuticals LLC3$99
Syndax Pharmaceuticals, Inc.4$93
Taiho Oncology, Inc.5$93
Sobi, Inc4$92
Clovis Oncology, Inc.6$88
Beone Medicines USA, Inc.5$86
Acceleron Pharma, Inc.5$81
Boehringer Ingelheim4$79
Lexicon Pharmaceuticals, Inc.4$66
Blueprint Medicines Corporation4$63
Emmaus Medical, Inc.3$57
Sun Pharmaceutical Industries Inc.2$52
Genmab U.S., Inc.3$51
Teva Pharmaceuticals USA, Inc.3$49
Mirati Therapeutics, Inc.3$44
Recordati_rare_diseases_inc.2$43
Verastem, Inc.3$41
Servier Pharmaceuticals LLC2$39
Morphosys, US Inc.2$37
Coherus Oncology, Inc.2$34

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,958 in reported general payments places this provider in the 80th percentile of 57 hematology & oncology providers in Mississippi.

See all hematology & oncology providers in Mississippi

Medicare billing

Part B allowed, 2024
$108,231
Medicare patients
515
Services billed
1,136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide34$816,061
RevlimidLenalidomide44$796,493
JakafiRuxolitinib Phosphate34$587,407
Lenalidomide30$336,746
ErleadaApalutamide24$335,096
ImbruvicaIbrutinib21$281,095
CalquenceAcalabrutinib Maleate15$206,090
BrukinsaZanubrutinib25$161,004
XareltoRivaroxaban101$84,518
EliquisApixaban37$20,650
EntrestoSacubitril/Valsartan15$12,557
ButransBuprenorphine14$7,185
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen119$2,534
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen47$2,086
Ondansetron Hcl57$2,044

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$1,223$816,06134 claims
Bristol Myers SquibbRevlimid$566$796,49344 claims
Incyte CorporationJakafi$1,042$587,40734 claims
Johnson & JohnsonErleada, Xarelto$1,629$419,613125 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$273$281,09521 claims
AstraZenecaCalquence$1,381$206,09015 claims
Beigene USA, Inc.Brukinsa$329$161,00425 claims
PfizerEliquis$829$20,65037 claims
NovartisEntresto$3,952$12,55715 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$49$53632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 57 hematology & oncology providers in Mississippi.

Other hematology & oncology in Gulfport

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →